The current study reported that HIF1α and TFE3 were implicated in the utilization of SHMT2 alternative promoter, resulting in expression of SHMT2 isoforms in cisplatin-resistant ovarian cancer cells under metabolic stress. This evidence concerns the gene SHMT2 and ovarian carcinoma.